Redefining the Practice of Medicine for Serious Infections
Redefining the Practice of Medicine for Serious Infections
Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections.
Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis’ monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption.
We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.
Arsanis was co-founded in 2010 by three infectious disease and industry veterans:
René Russo, PharmD, BCPS
President and Chief Executive Officer
René Russo, PharmD, BCPS, has spent more than 15 years in anti-infective R&D and has leadership experience across all phases of drug development, including global commercial launches for five novel antibacterial agents and clinical development and registration of several antiviral, antibacterial, and antifungal therapeutics. Her work has spanned the earliest phases of in vitro and animal work to clinical pharmacology, clinical development, and post-marketing clinical outcomes research.
Prior to Arsanis, Dr. Russo served in various roles over an 11-year period at Cubist Pharmaceuticals (Cubist). As Vice President of an 80+ person global team, Dr. Russo oversaw the clinical microbiology program (including extensive in vitro and animal work to support dose selection and PK/PD analyses), contributed to the design of multiple Phase 1 to Phase 3 clinical studies, and directly managed the oversight of several global burden of disease programs, including urosepsis and nosocomial pneumonia, to understand the outcomes and unmet medical needs in these infectious diseases. In her role at Cubist, she was also responsible for the oversight of more than 140 studies designed to further understand Gram-positive and Gram-negative infections, including epidemiology, resistance patterns, and the study of various treatments (including combination therapies) across nonclinical and clinical studies. Dr. Russo directly oversaw investigator-initiated research for a broad portfolio of anti-infectives, including daptomycin, fidaxomicin, ceftolozane/tazobactam, and tedizolid. Prior to her time at Cubist, Dr. Russo held roles of increasing responsibility at Bristol-Myers Squibb where she started her industry career as a Postdoctoral Fellow in Industrial Pharmacy Infectious Diseases. She also held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital before joining the biotechnology industry.
Dr. Russo received her PharmD and Bachelor of Science in Pharmacy from Rutgers University and holds a Board of Pharmacy Specialties Pharmacotherapy Certification (BCPS).
Eszter Nagy, MD, PhD
Co-Founder, Chief Scientific Officer, and Managing Director of Arsanis Biosciences GmbH
Eszter Nagy, MD, PhD, has spent 18 years in biotechnology and has been involved in the discovery and development of numerous biologics for infectious diseases. Her research and development experience includes bacterial pathogenesis, immune response to infections, protein-based vaccines for bacterial pathogens, vaccine adjuvants and anti-infective monoclonal antibodies.
Dr. Nagy founded Arsanis in 2010 and built a multi-disciplinary research and pre-clinical team in Vienna that created the current pipeline of the company, including Phase 2 readiness of the leading program ASN100.
Prior to Arsanis, Dr. Nagy served in various roles during her 12 years at Intercell AG (now Valneva SE), a biotechnology company focused on the development of prophylactic and therapeutic vaccines against infectious diseases. As Senior Vice President and Global Head of Research for Intercell, she directed research in antigen discovery using genomic, proteomic, and serological methods, pre-clinical development (toxicology and in vitro immune assays), as well as in vivo modeling of a wide range of experimental vaccines and monoclonal antibody therapies targeting bacterial and fungal pathogens.
Dr. Nagy co-founded EveliQure Biotechnologies (Vienna) in 2012, and was on the Board of Directors of WittyCell, S.A.S (now part of Abivax, SE), both vaccine development companies. Dr. Nagy is inventor on over 35 published patent families.
Prior to joining the biotechnology industry, Dr. Nagy spent 10 years in academic research. She is habil. professor at the University of Vienna, graduate student trainer, and author of over 65 scientific publications.
She was Associate Professor at the University Medical School of Pécs and a Visiting Scientist in the Department of Cancer Genetics at the Roswell Park Cancer Institute.
Dr. Nagy received her MD and PhD from the University Medical School of Pécs, Hungary, and was a Postdoctoral Fellow at Dartmouth Medical School.
Michael Gray, MBA, CPA
Chief Financial Officer and Chief Business Officer
Michael Gray, MBA, CPA, has nearly 20 years of industry business development and financial leadership experience, including financial strategy, planning, and operations.
Prior to Arsanis, Mr. Gray spent 15 years in leadership positions at Curis, Inc., a publicly-held oncology drug development company, including Chief Financial Officer, Chief Business Officer, and Chief Operating Officer. He was instrumental in financial and business development transactions that raised over $350 million for the company, including partnering, equity, and debt transactions. Previously, Mr. Gray held positions including Controller and de facto Chief Financial Officer of Reprogenesis, a biotechnology company focused on the development of cell therapy drug candidates. Mr. Gray has also served as an audit professional for the accounting and consulting firm of Ernst & Young, LLP.
Mr. Gray holds an active Certified Public Accountant license (Rhode Island). He earned his MBA in corporate finance and entrepreneurial management from the F.W. Olin Graduate School of Business at Babson College and a Bachelor of Science in Accounting from Bryant College.
Chris Stevens, MD
Chief Medical Officer
Chris Stevens, MD, has more than 17 years of biopharmaceutical drug development experience, including strategy, execution, and operations management for US and European clinical trials and regulatory filings, through senior management positions as a medical lead and as a leading industry consultant.
Prior to joining Arsanis, Dr. Stevens spent more than a decade consulting for nearly 30 companies assisting with all stages of drug development in the US and Europe. While working with Cubist Pharmaceuticals, he guided the development strategy for surotomycin for the treatment of C. difficile infection from IND filing to the completion of its successful Phase 2 trial. As a strategic consultant for Dyax, he supported the development of peptide and monoclonal antibody therapies for hereditary angioedema. He also served on the Millenium/Takeda team that led to the approval of vedolizumab for both the Crohn’s disease and ulcerative colitis treatment indications in the US and Europe. He served as Senior Vice President of Clinical Development at Alnara Pharmaceuticals and also previously held medical director roles at Circe Biomedical and Altus Pharmaceuticals. Dr. Stevens spent 10 years as a clinical and research gastroenterologist at Beth Israel Deaconess Medical Center in Boston and as an assistant professor of medicine at Harvard Medical School, during which he authored more than 30 peer-reviewed publications.
He holds a Bachelor of Arts in Chemistry from the University of North Carolina at Chapel Hill and earned his Medical Degree from the University of Miami.
David Mantus, PhD
Chief Development Officer
David Mantus, PhD, has more than 24 years of drug development experience, including clinical, regulatory, and manufacturing successes for programs in endocrinology, central nervous disorders, and infectious diseases. His work in infectious disease product development has included small molecules, microbiome-based therapeutics, immune globulins, monoclonal antibodies, and vaccines. Dr. Mantus has led teams responsible for all aspects of product development, from pre-IND through global commercialization and partnering. Prior to Arsanis, he held leadership roles in development at Seres Health, Cubist Pharmaceuticals, Shire Biologics, PAREXEL, and Procter & Gamble Pharmaceuticals. Previously, Dr. Mantus was a Postdoctoral Research Fellow in Biomedical Engineering at the University of Washington and Associate Professor of Pharmaceutical Sciences at MCPHS University. He is co-author of a book on regulatory affairs entitled, FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics, that is currently in its third edition.
Dr. Mantus received his Master of Science and PhD in Chemistry from Cornell University.
Partner, EMBL Ventures GmbH
Venture Partner, SV Life Sciences
Partner, OrbiMed Advisors
Founding Partner, Polaris Venture Partners
Co-Founder and CSO
Managing Partner, NeoMed
Managing Partner, SV Life Sciences
President and CEO
CEO, Arsia Therapeutics, President and CEO, Lyndra; Venture Partner, Polaris Venture Partners
The Arsanis Scientific Advisory Board members are international infectious diseases experts. They collectively hold extensive research, clinical and drug development expertise in anti-infectives, respiratory disease, intensive care unity medicine, and antibody engineering.
Paul G. Ambrose, PharmD, is President of the Institute for Clinical Pharmacodynamics, New York, USA; Honorary Research Fellow in Infectious Diseases at the University of Oxford, UK; and Adjunct Associate Research Professor at the University at Buffalo, New York. Dr. Ambrose brings translational expertise in the application of pharmacokinetic-pharmacodynamic principles, with research focusing on anti-infective translational science. Dr. Ambrose is the author of over 120 peer-reviewed scientific publications.
Birgitta Henriques-Normark, MD, PhD, is a Professor in medical microbial pathogenesis in the Department of Microbiology, Tumor, and Cell Biology at the Karolinska Institutet, as well as a Medical Doctor (MD) with a specialty in clinical bacteriology. Professor Henriques-Normark has extensive research and clinical expertise in host-bacterial interactions, ranging from bacterial regulatory systems to the immune response of the host, especially in the field of respiratory pathogens, mainly Streptococcus pneumoniae. Dr. Henriques-Normark has authored or co-authored more than 157 publications.
Rick Malley, MD, is Kenneth McIntosh Chair in Pediatric Infectious Diseases at Children's Hospital Boston and an Associate Professor of Pediatrics at Harvard Medical School. Besides being an active pediatric infectious disease clinician, his research laboratory focuses on pneumococcal pathogenesis and disease prevention with emphasis on correlates of protection and novel immune approaches based on vaccination. Dr. Malley has authored or co-authored 80 scientific publications in the field of infectious diseases.
Howard Mayer, MD, is Senior Vice President and Head of Global Clinical Development at Shire. Previously, Dr Mayer was Chief Medical Officer at EMD Serono, Head of Clinical Development and Medical Affairs for Virology at Pfizer leading the clinical development program of Selzentry, a novel oral entry inhibitor for the treatment of HIV/AIDS, and has worked on antibacterial drug development at Bristol-Myers Squibb. With Dr. Mayer’s extensive clinical and commercial expertise in anti-infective drug development, he was recognized in 2011 as one of PharmaVoice’s 100 Most Inspiring People in the Life Sciences Industry. Dr. Mayer has authored more than 70 publications and abstracts.
Steven M. Opal, MD, is Professor of Medicine in the Infectious Disease Division at The Warren Alpert Medical School of Brown University and Chief of Infectious Disease Division at Memorial Hospital of Rhode Island. Dr. Opal’s pivotal contributions to the infectious disease field include research on the patho-mechanism of septic shock, host-pathogen interaction in systemic infection, and antibiotic resistance; and clinical trial design, implementation, and analysis of data from Phase 1 to Phase 3 studies. He is the editor of several academic research journals and textbooks and the chair of the International Sepsis Forum.
Claire Poyart, MD, PhD, is Professor of Medical Microbiology, University Paris Descartes, and Head of the Laboratory of Bacteriology of Cochin Hospital Head of the National Reference Centre for Streptococci in France. As a clinical microbiologist, her clinical research focuses on the epidemiological characterization of Group B Streptococcus and the development of diagnostic tools for the detection and the identification of Gram-positive bacteria. Her basic research is directed towards characterizing streptococcal virulence and resulted in major contribution to the molecular understanding of the Group B Streptococcus disease mechanism. Dr. Poyart has authored and co-authored over 100 scientific publications in the fields of clinical microbiology and infectious diseases.
Antoni Torres, MD, PhD, FERS, is an internally recognized expert in ICU clinical medicine and respiratory disease. Professor Torres is Head of the Respiratory Intensive Care Unit, Department of Pneumology and Respiratory Allergy, Clinical Institute of the Thorax, Hospital Clinic of Barcelona and Coordinator of all the ICUs of the Clinic Thorax Institute. Professor Torres is also Professor of Medicine at Faculty of Medicine at the University of Barcelona, has authored or co-authored more than 350 original articles, and has coordinated or directed many research projects in the area of respiratory disease.
Richard Wunderink, MD, is Professor of Medicine in the Pulmonary and Critical Care Division of Northwestern University’s Feinberg School of Medicine and Medical Director of the Medical Intensive Care Unit, Northwestern Memorial Hospital. Professor Wunderink has specialty expertise in the areas of sepsis and pulmonary infections, especially ventilator-associated pneumonia and community-acquired pneumonia. Dr. Wunderink has authored or co-authored over 230 publications.
Marin Kollef, MD, FACP, FCCP, Chairman, is Professor of Medicine at the Washington University School of Medicine and Director of the Medical Intensive Care Unit and Respiratory Care Services at Barnes-Jewish Hospital in St. Louis, Missouri.
Paul G. Ambrose, PharmD, is President of the Institute for Clinical Pharmacodynamics, New York, USA; Honorary Research Fellow in Infectious Diseases at the University of Oxford, UK; and Adjunct Associate Research Professor at the University at Buffalo, New York. Dr. Ambrose is an editor for Antimicrobials Agents and Chemotherapy.
Philip S. Barie, MD, is Professor of Surgery at Weill Cornell Medical College and an attending surgeon at New York-Presbyterian/Weill Cornell Medical Center. He is also Chief, Preston A. Wade (Red) Acute Care Surgery Service, New York-Presbyterian Hospital, Weill Cornell Medical Center.
Helen W. Boucher, MD, is Director of the Infectious Diseases Fellowship Program and Ventricular Assist Device and Cardiac Transplant Infectious Diseases Program at Tufts Medical Center. She is an attending physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center and Associate Professor of Medicine at Tufts University School of Medicine.
Jean Chastre, MD, is a Consulting Professor, Medical ICU, Hospital Pitié-Salpêtrière, Paris.
Ralph Corey, MD, is Professor of Medicine, Infectious Disease, and Pathology; Gary Hock Professor of Global Health; and Vice-Chairman of the Department of Medicine at Duke University.
Vance Fowler, MD, is Professor of Medicine and Professor in Molecular Genetics and Microbiology at Duke University.
Bruno Francois, MD, is Specialist, Intensive Care Medicine at University Hospital of Limoges, France. Dr. Francois is also Head of the Limoges Clinical Investigational Center.
Howard Mayer, MD, is Senior Vice President and Head of Global Clinical Development at Shire Pharmaceuticals.
Vandana Menon, MD, PhD, MPH, is Vice President, Better Outcomes Corporation and Adjunct Associate Professor, Tufts-New England Medical Center.
Debra Poutsiaka, MD, PhD, is Associate Professor of Medicine, Tufts University School of Medicine and an Attending Physician, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center.
George Sakoulas, MD, is Associate Adjunct Professor, Division of Host-Microbe Systems and Therapeutics, Center for Immunity, Infection, and Inflammation, at the University of California San Diego School of Medicine.
Joseph Solomkin, MD, is Professor of Surgery (Emeritus), University of Cincinnati College of Medicine and the CEO of OASIS Global.
George Talbot, MD, is a Member and Immediate past Co-Chair of the ABSSSI/CABP and HABP/VABP Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health. Dr. Talbot is a Principal at Talbot Advisors, LLC.
Antoni Torres, MD, PhD, is Head, Respiratory Intensive Care Unit, Department of Pneumology and Respiratory Allergy at the Clinical Institute of the Thorax, Hospital Clinic of Barcelona.
Arsanis has successfully raised capital from top-tier life science investors OrbiMed, Polaris Ventures, SV Life Sciences, NeoMed, EMBL Ventures, The Bill & Melinda Gates Foundation, and GV, securing $85M since 2010.
Arsanis has also entered into multiple collaborations with leading industry, academic, and clinical research groups, building relationships with global leaders in the fields of antibody discovery and infectious diseases.
Arsanis’ lead clinical candidate, ASN100, and human mAbs in several pre-clinical programs (ASN400 and ASN500), were discovered in collaboration with Adimab, LLC, utilizing their industry premier human antibody discovery and optimization platform.